AAAAAA

   
Results: 1-19 |
Results: 19
Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs
Authors: Dunne, AL Mitchell, FM Coberly, SK Hellmann, NS Hoy, J Mijch, A Petropoulos, CJ Mills, J Crowe, SM
Citation: Al. Dunne et al., Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs, AIDS, 15(12), 2001, pp. 1471-1475
Cerebrospinal fluid response to structured treatment interruption after virological failure
Authors: Price, RW Paxinos, EE Grant, RM Drews, B Nilsson, A Hoh, R Hellmann, NS Petropoulos, CJ Deeks, SG
Citation: Rw. Price et al., Cerebrospinal fluid response to structured treatment interruption after virological failure, AIDS, 15(10), 2001, pp. 1251-1259
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
Authors: Deeks, SG Wrin, T Liegler, T Hoh, R Hayden, M Barbour, JD Hellmann, NS Petropoulos, CJ McCune, JM Hellerstein, MK Grant, RM
Citation: Sg. Deeks et al., Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia., N ENG J MED, 344(7), 2001, pp. 472-480
Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates
Authors: Duan, CY Poticha, D Stoeckli, TC Petropoulos, CJ Whitcomb, JM McHenry, CS Kuritzkes, DR
Citation: Cy. Duan et al., Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates, J INFEC DIS, 184(10), 2001, pp. 1336-1340
Reliability of C-min: Inhibitory concentration ratios - Reply
Authors: Condra, JH Petropoulos, CJ Ziermann, R Schleif, WA Shivaprakash, M Emini, EA
Citation: Jh. Condra et al., Reliability of C-min: Inhibitory concentration ratios - Reply, J INFEC DIS, 183(6), 2001, pp. 993-994
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant
Authors: Johnson, VA Petropoulos, CJ Woods, CR Hazelwood, JD Parkin, NT Hamilton, CD Fiscus, SA
Citation: Va. Johnson et al., Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant, J INFEC DIS, 183(11), 2001, pp. 1688-1693
Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients
Authors: Parkin, NT Deeks, SG Wrin, MT Yap, J Grant, RM Lee, KH Heeren, D Hellmann, NS Petropoulos, CJ
Citation: Nt. Parkin et al., Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients, AIDS, 14(18), 2000, pp. 2877-2887
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
Authors: Havlir, DV Hellmann, NS Petropoulos, CJ Whitcomb, JM Collier, AC Hirsch, MS Tebas, P Sommadossi, JP Richman, DD
Citation: Dv. Havlir et al., Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens, J AM MED A, 283(2), 2000, pp. 229-234
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
Authors: Petropoulos, CJ Parkin, NT Limoli, KL Lie, YS Wrin, T Huang, W Tian, H Smith, D Winslow, GA Capon, DJ Whitcomb, JM
Citation: Cj. Petropoulos et al., A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1, ANTIM AG CH, 44(4), 2000, pp. 920-928
Antiretroviral resistance during successful therapy of HIV type 1 infection
Authors: Martinez-Picado, J DePasquale, MP Kartsonis, N Hanna, GJ Wong, J Finzi, D Rosenberg, E Gunthard, HF Sutton, L Savara, A Petropoulos, CJ Hellmann, N Walker, BD Richman, DD Siliciano, R D'Aquila, RT
Citation: J. Martinez-picado et al., Antiretroviral resistance during successful therapy of HIV type 1 infection, P NAS US, 97(20), 2000, pp. 10948-10953
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir
Authors: Ziermann, R Limoli, K Das, K Arnold, E Petropoulos, CJ Parkin, NT
Citation: R. Ziermann et al., A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir, J VIROLOGY, 74(9), 2000, pp. 4414-4419
Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) frompatients with primary HIV infection to nonnucleoside reverse transcriptaseinhibitors is associated with variation at novel amino acid sites
Authors: Brown, AJL Precious, HM Whitcomb, JM Wong, JK Quigg, M Huang, W Daar, ES D'Aquila, RT Keiser, PH Connick, E Hellmann, NS Petropoulos, CJ Richman, DD Little, SJ
Citation: Ajl. Brown et al., Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) frompatients with primary HIV infection to nonnucleoside reverse transcriptaseinhibitors is associated with variation at novel amino acid sites, J VIROLOGY, 74(22), 2000, pp. 10269-10273
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
Authors: Condra, JH Petropoulos, CJ Ziermann, R Schleif, WA Shivaprakash, M Emini, EA
Citation: Jh. Condra et al., Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy, J INFEC DIS, 182(3), 2000, pp. 758-765
Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998
Authors: Weinstock, H Respess, R Heneine, W Petropoulos, CJ Hellmann, NS Luo, CC Pau, CP Woods, T Gwinn, M Kaplan, J
Citation: H. Weinstock et al., Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998, J INFEC DIS, 182(1), 2000, pp. 330-333
Quantitative competitive reverse transcription-PCR as a method to evaluateretrovirus removal during chromatography procedures
Authors: Lau, ASL Lie, YS Norling, LA Sernatinger, J Dinowitz, M Petropoulos, CJ Xu, YA
Citation: Asl. Lau et al., Quantitative competitive reverse transcription-PCR as a method to evaluateretrovirus removal during chromatography procedures, J BIOTECH, 75(2-3), 1999, pp. 105-115
Reduced antiretroviral drug susceptibility among patients with primary HIVinfection
Authors: Little, SJ Daar, ES D'Aquila, RT Keiser, PH Connick, E Whitcomb, JM Hellmann, NS Petropoulos, CJ Sutton, L Pitt, JA Rosenberg, ES Koup, RA Walker, BD Richman, DD
Citation: Sj. Little et al., Reduced antiretroviral drug susceptibility among patients with primary HIVinfection, J AM MED A, 282(12), 1999, pp. 1142-1149
Gibbon ape leukemia virus receptor functions of type III phosphate transporters from CHOK1 cells are disrupted by two distinct mechanisms
Authors: Chaudry, GJ Farrell, KB Ting, YT Schmitz, C Lie, YS Petropoulos, CJ Eiden, MV
Citation: Gj. Chaudry et al., Gibbon ape leukemia virus receptor functions of type III phosphate transporters from CHOK1 cells are disrupted by two distinct mechanisms, J VIROLOGY, 73(4), 1999, pp. 2916-2920
Phenotypic changes in drug susceptibility associated with failure of humanimmunodeficiency virus type 1 (HIV-1) triple combination therapy
Authors: Parkin, NT Lie, YS Hellmann, N Markowitz, M Bonhoeffer, S Ho, DD Petropoulos, CJ
Citation: Nt. Parkin et al., Phenotypic changes in drug susceptibility associated with failure of humanimmunodeficiency virus type 1 (HIV-1) triple combination therapy, J INFEC DIS, 180(3), 1999, pp. 865-870
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
Authors: Deeks, SG Hellmann, NS Grant, RM Parkin, NT Petropoulos, CJ Becker, M Symonds, W Chesney, M Volberding, PA
Citation: Sg. Deeks et al., Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome, J INFEC DIS, 179(6), 1999, pp. 1375-1381
Risultati: 1-19 |